Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
复制标题
DOI：
10.1182/blood-2011-04-347575
复制
发表时间：
2011-10-27
期刊：
影响因子：
20.3
通讯作者：
Mandelli, Franco
中科院分区：
文献类型：
--
作者：
Efficace, Fabio;Baccarani, Michele;Mandelli, Franco
本研究的主要目的是调查长期接受伊马替尼治疗的慢性粒细胞白血病 (CML) 患者与普通人群相比是否具有不同的健康相关生活质量 (HRQOL) 特征。总共招募了 448 名 CML 患者，并使用 SF-36 健康调查来比较一般 HRQOL 概况。还对症状进行了评估。 HRQOL 比较针对关键的可能混杂因素进行了调整。患者的中位年龄为 57 岁，伊马替尼治疗的中位时间为 5 年（范围 3-9 年）。最大的 HRQOL 差异出现在年轻患者中。特别是，年龄在 18 岁至 39 岁之间的患者由于身体和情感问题而在角色限制方面有明显的损害，分别为：-22.6 (P < .001)、-22.3 (P < .001)。 60 岁或以上的 CML 患者的 HRQOL 概况与一般人群报告的非常相似。与一般人群中的同龄人相比，女性的形象比男性差。疲劳是最常报告的症状。 CML 患者的 HRQOL 与许多地区的人群正常水平相当，但年轻和女性患者似乎报告了主要的局限性。 （血。2011；118（17）：4554-4560）
The main objective of this study was to investigate whether patients with chronic myeloid leukemia (CML) in treatment with long-term therapy imatinib have a different health-related quality-of-life (HRQOL) profile compared with the general population. In total, 448 CML patients were enrolled, and the SF-36 Health Survey was used to compare generic HRQOL profiles. Symptoms were also assessed. HRQOL comparisons were adjusted for key possible confounders. The median age of patients was 57 years and the median time of imatinib treatment was 5 years (range 3-9 years). The largest HRQOL differences were found in younger patients. In particular, patients aged between 18 and 39 years had marked impairments in role limitations because of physical and emotional problems, respectively: -22.6 (P < .001), -22.3 (P < .001). Patients with CML age 60 or older had a HRQOL profile very similar to that reported by the general population. Women had a worse profile than men when each were compared with their peers in the general population. Fatigue was the most frequently reported symptom. The HRQOL of CML patients is comparable with that of population norms in many areas, however, younger and female patients seem to report the major limitations. (Blood. 2011; 118(17): 4554-4560)